This site is intended only for healthcare professionals residing in Singapore




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsMaterialsVideosLet’s connectLet's ConnectContact usPfizer medical information
AMSResist the ResistanceAct now. Act how?Strategy to prevent catastropheSurveil. SurvivePolicy for PurposeBacterial InfectionsBacterial basicsDetection and selectionKnow the negativeThe HAP/VAP recapDispel the MBLPinpoint the positiveGo-to guidelinesFungal InfectionsFungal factsFind the fungiPolice the yeastBehold the mouldFight the fungiViral InfectionsVerdict on virusesResourcesViral Infections



Resist the ResistanceAct now. Act how?Strategy to prevent catastropheSurveil. SurvivePolicy for Purpose
Resist the resistance

Antimicrobial resistance (AMR) already causes more than 700,000 deaths globally per year.1 Without action, this number could rise to 10 million by 2050 – more than current deaths from cancer.2


Antimicrobial resistance is a serious threat to modern medicine and global health as we know it.1–3

Bacteria, fungi, and viruses are changing. Pathogens are gaining resistance against treatments designed to kill them.4,5 Overuse and misuse of antimicrobial medicines, climate change, increased international travel and trade, and sparse novel drug pipelines are all contributing to the problem.4,5

We need to find ways to preserve the effectiveness of these medicines, and fast. 
Drug-resistant infections are tough – and sometimes impossible – to treat.4

Antimicrobial stewardship (AMS) promotes the responsible use of anti-infectives and is critical to addressing antimicrobial resistance,1 but to work effectively it needs immediate and coordinated action.

How can we implement AMS? Take Action


For over 170 years, Pfizer has made significant contributions to improving health around the world, using science to create breakthroughs that help save patient’s lives.We're continuing our dedication to addressing evolving disease challenges and facing antimicrobial resistance head on.

Our comprehensive approach to stewardship ranges from education to research to patient engagement. We’re also the first pharmaceutical company to publicly share raw data through our antimicrobial surveillance website platform, the ATLAS (Antimicrobial Testing Leadership and Surveillance) database.7

As a result of our pioneering efforts, we have been recognized as the industry leader in antimicrobial stewardship in the Access to Medicine Foundation’s 2021 AMR Benchmark Report, which evaluates our industry’s progress in the fight against antimicrobial resistance.8

We also know the importance of a progressive clinical pipeline. Pfizer is one of the few large research-based pharmaceutical companies still active in R&D for anti-infectives.9 We continue to develop innovative treatments and vaccines, and solutions that go beyond medicine.

Even with one of the industry’s largest and most diverse portfolios of antimicrobials,9 we can’t fight this battle alone. Coming together as part of the broader infectious disease ecosystem is vital to the success of any stewardship initiative. 

The future of antimicrobials needs you.

How will we enact change against resistance?  Find Out Act now. Act how?

The fundamentals of antimicrobial stewardship

Explore More
AMR, antimicrobial resistance; AMS, antimicrobial stewardship; R&D, research and development; WHO, World Health Organization.ReferencesUnited Nations Interagency Coordination Group (IACG). No Time to Wait: Securing the future from drug-resistant infections. Available at: Accessed May 2023.O’Neill J. Tackling Drug-Resistant Infections Globally: Final report and recommendations the review on antimicrobial resistance. Available at: Accessed April 2023.World Health Organization. Global Action Plan (GAP) on Antimicrobial Resistance. Available at: Accessed May 2023.World Health Organization. Antimicrobial resistance. Available at: Accessed May 2023.United Nations. Bracing for Superbugs. Available at: Accessed May 2023.Pfizer Singapore. A Network Second to None. Available at: Accessed Aug 2023.Pfizer. Slowing the spread of Antimicrobial Resistance. Available at: Accessed May 2023.Access to Medicine Foundation. Antimicrobial resistance benchmark 2021. Available at: benchmark. Accessed May 2023.Pfizer. Our Commitment as a Global Anti-Infectives Leader. Available at: Accessed May 2023.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.

Copyright © 2024 Pfizer Limited. All rights reserved.